RESUMO
Objective This study aimed to understand the status of health-related quality of life (HRQOL) among the hospitalized patients with type 2 diabetes (T2DM) in Yinchuan, so as to analyze the factors associated with HRQOL of hospitalized T2DM patients. The applied value of quantile regression in analysis of HRQOL was explored. Methods A cross-sectional study was conducted to obtain data of 480 hospitalized T2DM patients. The Chinese Normal Audit of Diabetes-Dependent Quality of Life (CN-ADDQoL) scale was used to assess the HRQOL status of patients. Traditional linear regression and quantile regression were used to analyze the influencing factors of HRQOL in hospitalized T2DM patients. Results The average weight impact (AWI) of hospitalized T2DM patients was-2.7(-3.6,-1.9), and the items with lowest score were in the dimension of “work life” (AWI,-4(-6,-2)), “eat” AWI,-4(-6,-2)) and “Anything of Drinking” (AWI,-4(-6,-2)). Linear regression results showed that 18-59 years old or the renal and circulatory complications were risk factors for HRQOL in T2DM hospitalized patients. Quantile regression further found that the better the quality of life, the weaker the effect on age (β1=0.931, P1=0.001; β2=0.699, P2=0.001; β3=0.370, P3=0.012; β4=0.313, P4=0.035), the rural residents (β5=-0.421, P5<0.001), insulin treatment (β3=-0.325; P3=0.024), the ocular (β1=-0.546, P1=0.008; β5=-0.352, P5=0.008), renal (β5=-0.358, P5=0.025) and circulatory complications (β1=-0.803, P1<0.001; β5=-0.302, P5=0.011) had effect on HRQOL at different quantiles. Conclusions Age, urban and rural residence, whether receive insulin therapy and complications are the influencing factors of HRQOL in hospitalized T2DM patients. The quantile regression model can show different factors affecting the quality of life of patients at different quintiles. The results from quantile regression can provide the targeted and reasonable recommendations for improvement of HRQOL of T2DM patients.
RESUMO
Three candidate antisense target sites of mouse Fas gene were screened by PARASS (poly-A anchored RNA accessible sites screening) technology. They were target at Fas gene 297nt-317nt, 618nt- 638nt and 662nt-682nt. Antisense oligos (A1, A2 and A3) and DNAzymes (D1, D2, and D3) for every target site were designed and synthesized. In vitro, the validation of the sites were judged by antisense oligos included RNase H splicing and the DNAzyme degradation. The results indicated that A1, A2 and A3 introduced RNase H degradation. DNAzymes D1, D2 and D3 cleaved Fas mRNA effectively. Neither degradation observed in antisense oligo RNase H group in non-target site (1211-1231nt) and 2 bases mismatched of A3, nor splicing occurred in DNzyme group in non-target site ( 1211-1231nt) and 2 bases mismatched of D3. Site 2 and 3 were at the same positions with those of ISIS Pharmaceuticals. The effective antisense oligos and DNAzymes for Fas gene could be used for the research subsequently.